Literature DB >> 2510699

The Yale-Brown Obsessive Compulsive Scale. II. Validity.

W K Goodman1, L H Price, S A Rasmussen, C Mazure, P Delgado, G R Heninger, D S Charney.   

Abstract

The development design and reliability of the Yale-Brown Obsessive Compulsive Scale have been described elsewhere. We focused on the validity of the Yale-Brown Scale and its sensitivity to change. Convergent and discriminant validity were examined in baseline ratings from three cohorts of patients with obsessive-compulsive disorder (N = 81). The total Yale-Brown Scale score was significantly correlated with two of three independent measures of obsessive-compulsive disorder and weakly correlated with measures of depression and of anxiety in patients with obsessive-compulsive disorder with minimal secondary depressive symptoms. Results from a previously reported placebo-controlled trial of fluvoxamine in 42 patients with obsessive-compulsive disorder showed that the Yale-Brown Scale was sensitive to drug-induced changes and that reductions in Yale-Brown Scale scores specifically reflected improvement in obsessive-compulsive disorder symptoms. Together, these studies indicate that the 10-item Yale-Brown Scale is a reliable and valid instrument for assessing obsessive-compulsive disorder symptom severity and that it is suitable as an outcome measure in drug trials of obsessive-compulsive disorder.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2510699     DOI: 10.1001/archpsyc.1989.01810110054008

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  480 in total

1.  Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism.

Authors:  G DelGiudice-Asch; L Simon; J Schmeidler; C Cunningham-Rundles; E Hollander
Journal:  J Autism Dev Disord       Date:  1999-04

2.  Evidence for cortical inhibitory and excitatory dysfunction in obsessive compulsive disorder.

Authors:  Margaret A Richter; Danilo R de Jesus; Sylco Hoppenbrouwers; Melissa Daigle; Jasna Deluce; Lakshmi N Ravindran; Paul B Fitzgerald; Zafiris J Daskalakis
Journal:  Neuropsychopharmacology       Date:  2011-12-14       Impact factor: 7.853

3.  Positron emission tomography experience with 2-[¹⁸F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[¹⁸F]FA) in the living human brain of smokers with paranoid schizophrenia.

Authors:  James Robert Brašić; Nicola Cascella; Anil Kumar; Yun Zhou; John Hilton; Vanessa Raymont; Andrew Crabb; Maria Rita Guevara; Andrew G Horti; Dean Foster Wong
Journal:  Synapse       Date:  2011-12-29       Impact factor: 2.562

Review 4.  Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-V?

Authors:  Katharine A Phillips; Dan J Stein; Scott L Rauch; Eric Hollander; Brian A Fallon; Arthur Barsky; Naomi Fineberg; David Mataix-Cols; Ygor Arzeno Ferrão; Sanjaya Saxena; Sabine Wilhelm; Megan M Kelly; Lee Anna Clark; Anthony Pinto; O Joseph Bienvenu; Joanne Farrow; James Leckman
Journal:  Depress Anxiety       Date:  2010-06       Impact factor: 6.505

5.  EEG-vigilance differences between patients with borderline personality disorder, patients with obsessive-compulsive disorder and healthy controls.

Authors:  Ulrich Hegerl; Michael Stein; Christoph Mulert; Roland Mergl; Sebastian Olbrich; Eva Dichgans; Dan Rujescu; Oliver Pogarell
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-04       Impact factor: 5.270

6.  Value-based decision making under uncertainty in hoarding and obsessive- compulsive disorders.

Authors:  Helen Pushkarskaya; David Tolin; Lital Ruderman; Daniel Henick; J MacLaren Kelly; Christopher Pittenger; Ifat Levy
Journal:  Psychiatry Res       Date:  2017-08-24       Impact factor: 3.222

7.  Intolerance of uncertainty: a common factor in the treatment of emotional disorders.

Authors:  James F Boswell; Johanna Thompson-Hollands; Todd J Farchione; David H Barlow
Journal:  J Clin Psychol       Date:  2013-02-04

8.  Behavioral avoidance predicts treatment outcome with exposure and response prevention for obsessive-compulsive disorder.

Authors:  Michael G Wheaton; Marina Gershkovich; Thea Gallagher; Edna B Foa; H Blair Simpson
Journal:  Depress Anxiety       Date:  2018-02-02       Impact factor: 6.505

9.  Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - a [11C]DASB PET study.

Authors:  M Reimold; M N Smolka; A Zimmer; A Batra; A Knobel; C Solbach; A Mundt; H U Smoltczyk; D Goldman; K Mann; G Reischl; H-J Machulla; R Bares; A Heinz
Journal:  J Neural Transm (Vienna)       Date:  2007-08-22       Impact factor: 3.575

Review 10.  Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.

Authors:  Anjali L Varigonda; Ewgeni Jakubovski; Michael H Bloch
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2016-08-04       Impact factor: 8.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.